FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085267090> ?p ?o ?g. }

• W2085267090 endingPage "773" @default.
• W2085267090 startingPage "766" @default.
• W2085267090 abstract "To determine the safety and efficacy of intravenous (IV) pamidronate treatment in ankylosing spondylitis (AS) patients who have had a suboptimal response to nonsteroidal antiinflammatory drugs (NSAIDs).Pamidronate at 60 mg was compared with pamidronate at 10 mg rather than placebo in view of the high incidence of transient arthralgias upon first IV exposure to the drug. The drug were given monthly for 6 months in a randomized double-blind, controlled trial. The inclusion criterion was active disease (Bath AS Disease Activity Index [BASDAI] of > or = 4 or morning stiffness of > or = 45 minutes) despite stable NSAID therapy. The primary outcome measure was the BASDAI, and secondary outcomes included the Bath AS Functional Index (BASFI), Bath AS Global Index (BASGI), Bath AS Metrology Index (BASMI), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and percentage of patients achieving a reduction of > or = 25% in the BASDAI. Outcome assessments were done at -2, 0, 12, and 24 weeks, and analysis was by intent to treat.Eighty-four AS patients (67 men and 17 women; mean age 39.6 years and mean disease duration 15.1 years) were enrolled. Dosage groups were well matched at baseline for demographics, disease activity, and functional indices. At 6 months, the mean BASDAI had decreased by 2.22 (34.5%) in the 60-mg group and by 0.93 (15%) in the 10-mg group (P = 0.002). Significantly greater reductions in the 60-mg group were also noted for the BASFI (P < 0.001), BASGI (P = 0.01), and BASMI (P = 0.03). Significantly more patients achieved a reduction of > or = 25% in the BASDAI in the 60-mg group versus the 10-mg group (63.4% versus 30.2%; P = 0.004). Differences in ESR/CRP were not significant (NS). Withdrawals included 9 (20.9%) from the 10-mg group and 3 (7.3%) from the 60-mg group (P NS). Adverse events were confined to transient arthralgias/myalgias after the first IV infusion, occurring in 68.3% and 46.5% of patients in the 60-mg and 10-mg groups, respectively (P NS).Pamidronate has dose-dependent therapeutic properties in AS." @default.
• W2085267090 created "2016-06-24" @default.
• W2085267090 creator A5001511197 @default.
• W2085267090 creator A5018502570 @default.
• W2085267090 creator A5019670095 @default.
• W2085267090 creator A5028274603 @default.
• W2085267090 creator A5046007575 @default.
• W2085267090 creator A5050415571 @default.
• W2085267090 creator A5052694277 @default.
• W2085267090 creator A5053859070 @default.
• W2085267090 creator A5064680897 @default.
• W2085267090 creator A5069979151 @default.
• W2085267090 creator A5071007504 @default.
• W2085267090 creator A5076712847 @default.
• W2085267090 date "2002-03-01" @default.
• W2085267090 modified "2023-09-26" @default.
• W2085267090 title "A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis" @default.
• W2085267090 cites W1864497115 @default.
• W2085267090 cites W1964150737 @default.
• W2085267090 cites W1965212418 @default.
• W2085267090 cites W1966756689 @default.
• W2085267090 cites W1967789788 @default.
• W2085267090 cites W1967875617 @default.
• W2085267090 cites W1974903174 @default.
• W2085267090 cites W1974903457 @default.
• W2085267090 cites W1979232932 @default.
• W2085267090 cites W1988407233 @default.
• W2085267090 cites W1996593783 @default.
• W2085267090 cites W1997637714 @default.
• W2085267090 cites W2001735552 @default.
• W2085267090 cites W2005088248 @default.
• W2085267090 cites W2020869366 @default.
• W2085267090 cites W2024479120 @default.
• W2085267090 cites W2024887507 @default.
• W2085267090 cites W2030126283 @default.
• W2085267090 cites W2031575345 @default.
• W2085267090 cites W2035612894 @default.
• W2085267090 cites W2045369683 @default.
• W2085267090 cites W2049818198 @default.
• W2085267090 cites W2052659304 @default.
• W2085267090 cites W2062544882 @default.
• W2085267090 cites W2093164779 @default.
• W2085267090 cites W2126496903 @default.
• W2085267090 cites W2130924661 @default.
• W2085267090 cites W2140235660 @default.
• W2085267090 cites W2145741990 @default.
• W2085267090 cites W2160367898 @default.
• W2085267090 cites W2168058439 @default.
• W2085267090 cites W2168633120 @default.
• W2085267090 cites W2329359808 @default.
• W2085267090 cites W4241845546 @default.
• W2085267090 doi "https://doi.org/10.1002/art.10139" @default.
• W2085267090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11920413" @default.
• W2085267090 hasPublicationYear "2002" @default.
• W2085267090 type Work @default.
• W2085267090 sameAs 2085267090 @default.
• W2085267090 citedByCount "213" @default.
• W2085267090 countsByYear W20852670902012 @default.
• W2085267090 countsByYear W20852670902013 @default.
• W2085267090 countsByYear W20852670902014 @default.
• W2085267090 countsByYear W20852670902015 @default.
• W2085267090 countsByYear W20852670902016 @default.
• W2085267090 countsByYear W20852670902017 @default.
• W2085267090 countsByYear W20852670902018 @default.
• W2085267090 countsByYear W20852670902019 @default.
• W2085267090 countsByYear W20852670902020 @default.
• W2085267090 countsByYear W20852670902021 @default.
• W2085267090 countsByYear W20852670902022 @default.
• W2085267090 countsByYear W20852670902023 @default.
• W2085267090 crossrefType "journal-article" @default.
• W2085267090 hasAuthorship W2085267090A5001511197 @default.
• W2085267090 hasAuthorship W2085267090A5018502570 @default.
• W2085267090 hasAuthorship W2085267090A5019670095 @default.
• W2085267090 hasAuthorship W2085267090A5028274603 @default.
• W2085267090 hasAuthorship W2085267090A5046007575 @default.
• W2085267090 hasAuthorship W2085267090A5050415571 @default.
• W2085267090 hasAuthorship W2085267090A5052694277 @default.
• W2085267090 hasAuthorship W2085267090A5053859070 @default.
• W2085267090 hasAuthorship W2085267090A5064680897 @default.
• W2085267090 hasAuthorship W2085267090A5069979151 @default.
• W2085267090 hasAuthorship W2085267090A5071007504 @default.
• W2085267090 hasAuthorship W2085267090A5076712847 @default.
• W2085267090 hasConcept C126322002 @default.
• W2085267090 hasConcept C141071460 @default.
• W2085267090 hasConcept C142724271 @default.
• W2085267090 hasConcept C168563851 @default.
• W2085267090 hasConcept C204787440 @default.
• W2085267090 hasConcept C27081682 @default.
• W2085267090 hasConcept C2776260265 @default.
• W2085267090 hasConcept C2777402515 @default.
• W2085267090 hasConcept C2777453003 @default.
• W2085267090 hasConcept C2778143017 @default.
• W2085267090 hasConcept C2779134260 @default.
• W2085267090 hasConcept C2780415856 @default.
• W2085267090 hasConcept C71924100 @default.
• W2085267090 hasConcept C90924648 @default.
• W2085267090 hasConceptScore W2085267090C126322002 @default.
• W2085267090 hasConceptScore W2085267090C141071460 @default.

• next